|Bid||90.00 x 1300|
|Ask||91.03 x 800|
|Day's range||89.49 - 92.28|
|52-week range||30.05 - 189.89|
|Beta (5Y monthly)||1.51|
|PE ratio (TTM)||5.70|
|Earnings date||06 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||115.33|
TEMPLE CITY, Calif., September 23, 2021--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will be partnering with the Houston Health Department and Houston-area public schools to provide COVID-19 testing to students during the current school year.
Jason Hawthorne (Repligen): Repligen might fly under the radar, but it serves an important role in a fast-growing industry. The stock price reinforces that. The company has benefited from the adoption of biologic drugs over traditional small-molecule chemical compounds.
There were a lot of companies that jumped to action last year in the fight against the SARS-CoV-2 virus. In that latter category, one company proved it has a business model to succeed long after the pandemic ends -- assuming it ever does. Fulgent Genetics (NASDAQ: FLGT) burst onto the scene when the Food and Drug Administration (FDA) approved its test for detecting COVID-19 in June 2020.